Open AccessIntracellular delivery of nanoparticles fabricated from monoclonal and polyclonal antibodies against influenza A and hepatitis B virus antigens
Author(s) -
О. В. Морозова,
Elizaveta R. Pavlova,
Е. И. Исаева,
A. I. Sokolova,
Ekaterina A. Obraztsova,
E.A. Ivleva,
Dmitry V. Klinov
Publication year - 2020
Publication title -
iop conference series. materials science and engineering
Language(s) - English
Resource type - Journals
eISSN - 1757-899X
pISSN - 1757-8981
DOI - 10.1088/1757-899x/876/1/012001
Subject(s) - polyclonal antibodies , monoclonal antibody , antigen , intracellular , hbsag , virology , hepatitis b virus , microbiology and biotechnology , virus , biology , monoclonal , antibody , chemistry , immunology
Specific antibodies (AB) may serve as molecular tools for both targeted, etiotropic and immunomodulation therapy of the infectious and oncological diseases. Despite their ability to bind with extracellular virions and isolated viral antigens AB may not pass through host cell membranes to inhibit intracellular infectious agents. Nanoparticles (NP) were fabricated from polyclonal and monoclonal AB against the influenza A structural and non-structural proteins as well as against the hepatitis B virus surface antigen (HBsAg). ELISA and immunofluorescent analysis revealed the ligand-binding activity of the AB NP comparable with the properties of the original AB. Fluorescent microscopy and quantitation showed efficient cellular uptake of the labeled AB NP and their degradation in 5 days posttreatment. Intracellular AB NP induced interferon (IFN) gene expression but not interleukin (IL) 4 and IL10 transcription. The cytokines mediated immunomodulation potential of the protein NP.